Skip to content
HowShorted

SpringWorks Therapeutics, Inc. short interest in 2023

In 2023, SpringWorks Therapeutics, Inc.'s disclosed short interest ran from 20.01% of shares outstanding on 13 Jan 2023 to 17.91% on 29 Dec 2023, a change of -2.10 percentage points. The year's high was 24.11% on 31 Jul 2023 and its low 15.78% on 15 Nov 2023, averaging 19.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.64 days on 14 Jul 2023. Full history: SpringWorks Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for SpringWorks Therapeutics, Inc. in 2023

2023 in figures

Start of year
20.01% (13 Jan 2023)
End of year
17.91% (29 Dec 2023)
Change
-2.10 pp
High
24.11% (31 Jul 2023)
Low
15.78% (15 Nov 2023)
Average
19.92%
Highest days to cover
36.64 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

SpringWorks Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202320.01%15.05
31 Jan 202319.64%21.44
15 Feb 202318.32%19.28
28 Feb 202318.63%17.3010-K filed, results (8-K)
15 Mar 202319.83%14.59
31 Mar 202318.69%14.34
14 Apr 202317.93%20.41
28 Apr 202318.50%20.34
15 May 202319.18%17.2910-Q filed, results (8-K)
31 May 202319.77%19.05
15 Jun 202321.94%19.23
30 Jun 202323.90%15.66
14 Jul 202323.88%36.64
31 Jul 202324.11%35.40
15 Aug 202324.11%30.7810-Q filed, results (8-K)
31 Aug 202323.22%24.77
15 Sep 202323.30%22.59
29 Sep 202322.74%31.55
13 Oct 202316.61%18.76
31 Oct 202316.31%19.01
15 Nov 202315.78%11.6410-Q filed, results (8-K)
30 Nov 202316.28%5.49
15 Dec 202317.57%5.42
29 Dec 202317.91%10.19

See also: SpringWorks Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.